Paragon 28, Inc. (FNA)
| Market Cap | 728.97M |
| Revenue (ttm) | 216.39M |
| Net Income (ttm) | -47.84M |
| Shares Out | 82.84M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 544,561 |
| Open | 8.95 |
| Previous Close | 8.97 |
| Day's Range | 8.73 - 9.18 |
| 52-Week Range | 7.95 - 19.72 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+138.64%) |
| Earnings Date | May 8, 2024 |
About FNA
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunio... [Read more]
Financial Performance
In 2023, Paragon 28's revenue was $216.39 million, an increase of 19.30% compared to the previous year's $181.38 million. Losses were -$47.84 million, -28.94% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for FNA stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 138.64% from the latest price.
News
Appointment of Stephen M. Deitsch as new Chief Financial Officer
OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normot...
NeuroStreet To Transform Trading Technology With Tickblaze Acquisition
OTTAWA, Ontario--(BUSINESS WIRE)--NeuroStreet acquires TickBlaze to elevate trading tech, promising transformative solutions in the industry.
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), (“Paragon 28” or “the Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today an...
Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior ...
Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...
Paragon 28 to Present at the CG 2024 Musculoskeletal Conference
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...
Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report fina...
Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy u...
Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System...
Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis lon...
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a...
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
ENGLEWOOD, Co.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company's position in the ...
Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...
Paragon 28 Launches BEAST™ Cortical Fibers Expanding its Biologics Portfolio
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular attachment...
Paragon 28 Launches JAWS™ Great White Staple System Further Expanding its Nitinol Staple Offering
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System which was developed to provide for increased strength and stabi...
Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile lab training program making it even more convenient for...
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announc...
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...
Paragon 28 to Present at Upcoming Investor Conferences
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...
Paragon 28 To Report Third Quarter Financial Results on November 7, 2023
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report fina...
Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for ...
Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...
Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...
Paragon 28 to Present at the Canaccord Genuity 43rd Annual Growth Conference
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...
Paragon 28 To Report Second Quarter Financial Results on August 2, 2023
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report fina...